MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Kymera Therapeutics Inc

Open

SectorGezondheidszorg

33.33 2.74

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

32.02

Max

33.81

Belangrijke statistieken

By Trading Economics

Inkomsten

-8.3M

-71M

Verkoop

3.7M

7.4M

EPS

-0.89

Winstmarge

-956.884

Werknemers

188

EBITDA

-8.3M

-69M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+80.98% upside

Dividenden

By Dow Jones

Volgende Winsten

9 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-523M

1.8B

Vorige openingsprijs

30.59

Vorige sluitingsprijs

33.33

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

Kymera Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 nov 2024, 03:00 UTC

Top Nieuws

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

9 jul 2024, 09:05 UTC

Top Nieuws

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

Peer Vergelijking

Prijswijziging

Kymera Therapeutics Inc Prognose

Koersdoel

By TipRanks

80.98% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 55.56 USD  80.98%

Hoogste 72 USD

Laagste 49 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kymera Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

10

Buy

1

Hold

0

Sell

Technische score

By Trading Central

25.43 / N/ASteun & Weerstand

Korte Termijn

Very Strong Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Strong Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.